← Evidence map

ArticleBMC gastroenterology2026

Dual GIP/GLP-1 receptor agonist tirzepatide ameliorates hepatic steatosis and inflammatory responses in a MASLD mouse model associated with the CCL2/CCR2 axis.

Yongning Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Dual GIP/GLP-1 receptor agonist tirzepatide ameliorates hepatic steatosis and inflammatory responses in a MASLD mouse model associated with the CCL2/CCR2 axis. | Socratic